Vaxin Inc. nabbed its new CEO from a competitor and charged him with soliciting $20 million in venture capital to transition the biotech firm’s experimental flu drugs into commercial products.
Vaxin Inc. nabbed its new CEO from a competitor and charged him with soliciting $20 million in venture capital to transition the biotech firm’s experimental flu drugs into commercial products.